Testing options

The information gained from testing gives you and your family members the best chance at reducing your risk of future cancers. If you and your doctor decide that you are a candidate for genetic testing, there are many options available from Myriad Genetic Laboratories.

Myriad myRisk™ Hereditary Cancer

This test is a hereditary cancer panel that analyzes multiple genes, including BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, MYH and others. Myriad myRisk combines genetic information with the personal and family history you give your healthcare provider to generate guideline-based management options to help you lower cancer risks.

When Myriad myRisk was launched in 2013, it became the first test to analyze a patient’s genetic test status and clinical/family history , and represented the next-generation of hereditary cancer testing. With the addition of riskScore, myriad myRisk now provides an even more comprehensive assessment of a patient’s risk for developing breast cancer by blending  well-defined highly and moderately penetrant hereditary cancer genes, clinical risk factors, and other genetic markers.

Myriad myRisk™ riskScore™

riskScore is a breast cancer risk estimation result that provides some women who have not had breast cancer with a personalized assessment of their 5-year and remaining lifetime breast cancer risk. It can help identify a more accurate and comprehensive lifetime breast cancer risk estimate in individuals who are candidates for hereditary cancer testing. With Myriad’s industry leading accuracy, the level of confidence that riskScore provides is unparalleled.

BRACAnalysis®: a test for Hereditary Breast and Ovarian Cancer syndrome (HBOC)

  • Integrated BRACAnalysis – This test is used if no one else in your family has been tested, or no one else has had a positive result for a gene mutation. It checks for mutations in the BRCA1 and BRCA2 genes associated with HBOC syndrome.
  • Single Site BRACAnalysis – When a gene mutation has been previously identified in another family member, this screening test will look for that specific mutation only.
  • Multisite 3 BRACAnalysis – This BRACAnalysis test is used for the three most common mutations found in people of Ashkenazi, or Eastern European, Jewish ancestry.

COLARIS®: a test for Hereditary Colon Cancer

  • COLARISPLUS – This test is used if no one else in your family has been tested or no one else has had a positive result for a gene mutation. It checks for gene mutations in the following genes: MLH1, MSH2, MSH6, PMS2,EPCAM, and MYH.
  • COLARIS AP®PLUS – This test aids assessment of the risk of developing hereditary colorectal polyps; it detects mutations in the APC and MYH genes, which cause adenomatous polyposis colon cancer syndromes.
  • Single Site COLARIS or Single Site COLARIS AP – This test is used if there is a known gene mutation in your family so your healthcare professional can look for a specific mutation.
  • Gene-Specific COLARIS – This test is appropriate for individuals with cancer who have had tumor analysis indicating they might have Lynch syndrome.

Unique tests to aid cancer treatment planning

Additional testing is also available to help those who have already been diagnosed with cancer. A doctor might order one of these tests to learn more about tumor behavior or an individual patient’s possible response to therapy. The results of these tests help to make personalized treatment possible.


a test to assess prostate cancer aggressiveness

This test measures the expression levels of the genes involved in cell cycle progression. At the time of diagnosis, Prolaris can help to identify patients with less aggressive cancer who may be candidates for active surveillance. In addition, Prolaris can identify patients who appear clinically low-risk but have a more aggressive disease that requires more aggressive treatment. Visit Prolaris.com to learn more about this unique test.

Learn More


EndoPredict is a genomic test for people newly diagnosed with early-stage, estrogen-receptor-positive, HER2-negative breast cancer. Research shows that the EndoPredict test may be widely used to help make treatment decisions based on the cancer’s risk of coming back in a part of the body away from the breast (distant metastasis) within 10 years after diagnosis. EndoPredict provides a risk score that is either low-risk or high-risk of breast cancer recurring as distant metastasis. Knowing if the cancer has a high or low risk of recurrence can help women and their doctors decide if chemotherapy or other treatments to reduce risk after surgery are needed.

Learn More

myChoice HRD

myChoice HRD identifies patients that are most likely to benefit from PARP inhibitors. Every patient’s cancer is unique, so their treatment should be as well. Myriad’s myChoice HRD helps physicians select the most effective treatment for their patients, minimizing the time and toxicity associated with ineffective therapies.

Learn More

BRACAnalysis CDX

BRACAnalysis CDx helps inform patient management related to the PARP inhibitors Lynparza (olaparib) and Zejula™ (niraparib). It is the only FDA-approved laboratory developed test approved to be used to inform treatment decisions for the PARP inhibitor, Lynparza. A positive BRACAnalysis CDx result in patients with ovarian cancer is also associated with enhanced progression-free survival (PFS) from Zejula™ (niraparib) maintenance therapy.

Learn More

Recommended Links